Milestone Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Regulatory and Corporate Update
Resolution of CRL Manufacturing issues in progress - Type A meeting requested
No clinical safety or efficacy concerns raised by FDA
MONTREAL and CHARLOTTE, N.C., May 14, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the first quarter ended March 31, 2025. The Company also announced the submission of a meeting request to the U.S. Food and Drug Administration (FDA) as the next step in the resolution of CRL issues.
'Our immediate priority is to engage with the U.S. FDA in order to address the CMC-related issues raised in the CRL received for CARDAMYST as a treatment for PSVT,' said Joe Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. 'We are confident we can work with the FDA to fully respond to the CRL and remain committed to the potential of CARDAMYST. If approved, it will be the first and only self-administered therapy for the rapid termination of episodes of PSVT.'
First Quarter and Recent Program Updates
Etripamil for Patients with PSVT
Etripamil for patients with atrial fibrillation with rapid ventricular rate (AFib-RVR)
First Quarter 2025 Financial Results
For further details on the Company's financials, refer to the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the SEC.
About Etripamil
Etripamil is Milestone's lead investigational product. It is a novel calcium channel blocker nasal spray under clinical development for frequent and often highly symptomatic episodes of PSVT and AFib-RVR. It is designed as a self-administered rapid response therapy for patients thereby bypassing the need for immediate medical oversight. If approved, etripamil is intended to provide health care providers with a new treatment option to enable on-demand care and patient self-management. This portable, self-administered treatment may provide patients with active management and a greater sense of control over their condition. CARDAMYST™, the conditionally approved brand name for etripamil nasal spray, is well studied with a robust clinical trial program that includes a completed Phase 3 clinical-stage program for the treatment of PSVT and Phase 2 trial for the treatment of patients with AFib-RVR.
About Milestone Pharmaceuticals
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular solutions to improve the lives of people living with complex and life-altering heart conditions. The Company's focus on understanding unmet patient needs and improving the patient experience has led us to develop new treatment approaches that provide patients with an active role in self-managing their care. Milestone's lead investigational product is etripamil, a novel calcium channel blocker nasal spray that is being studied for patients to self-administer without medical supervision to treat symptomatic episodic attacks associated with PSVT and AFib-RVR.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'believe,' 'continue,' 'could,' 'demonstrate,' 'designed,' 'develop,' 'estimate,' 'expect,' 'may,' 'pending,' 'plan,' 'potential,' 'progress,' 'will', 'intend' and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Milestone's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include statements regarding: the outcomes of future interactions with the FDA, including the potential Type A meeting; Milestone's ability to address the issues raised in the CRL on a timely basis, if at all; the outcome of the potential NDA resubmission; CARDAMYST's potential as a novel treatment option to help patients with PSVT; potential protections afforded by U.S. patents; CARDAMYST's ability to make the biggest difference in patient health, as compared to other available treatment options; the timing of patient enrollment in the Phase 3 study of etripamil for AFib-RVR; and other statements not related to historical facts. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, but are not limited to, whether our future interactions with the FDA will have satisfactory outcomes; whether and when, if at all, our NDA for etripamil will be approved by the FDA; uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of our clinical trials; risks and uncertainty related to the complexity inherent in cleaning, verifying and analyzing trial data; and whether the clinical trials will validate the safety and efficacy of etripamil for PSVT or other indications, among others, general economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, international tariffs, Russian hostilities in Ukraine and ongoing disputes in Israel and Gaza and overall fluctuations in the financial markets in the United States and abroad, risks related to pandemics and public health emergencies, and risks related the sufficiency of Milestone's capital resources and its ability to raise additional capital in the current economic climate. These and other risks are set forth in Milestone's filings with the U.S. Securities and Exchange Commission (SEC), including in its annual report on Form 10-K for the year ended December 31, 2025 and its quarterly report on Form 10-Q for the quarter ended March 31, 2025, in each case under the caption 'Risk Factors,' as such discussions may be updated from time to time by subsequent filings Milestone may make with the SEC. Except as required by law, Milestone assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Contact:
Kim Fox, Vice President, Communications, [email protected]
Investor Relations
Kevin Gardner, [email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
43 minutes ago
Supreme Court widens court options for vaping companies pushing back against FDA rules
WASHINGTON -- WASHINGTON (AP) — The Supreme Court sided with e-cigarette companies on Friday in a ruling making it easier to sue over Food and Drug Administration decisions blocking their products from the multibillion-dollar vaping market. The 7-2 opinion comes as companies push back against a yearslong federal regulatory crackdown on electronic cigarettes. It's expected to give the companies more control over which judges hear lawsuits filed against the agency. The justices went the other way on vaping in an April decision, siding with the FDA in a ruling upholding a sweeping block on most sweet-flavored vapes instituted after a spike in youth vaping. The current case was filed by R.J. Reynolds Vapor Co., which had sold a line of popular berry and menthol-flavored vaping products before the agency started regulating the market under the Tobacco Control Act in 2016. The agency refused to authorize the company's Vuse Alto products, an order that 'sounded the death knell for a significant portion of the e-cigarette market,' Justice Amy Coney Barrett wrote in the majority opinion. The company is based in North Carolina and typically would have been limited to challenging the FDA in a court there or in the agency's home base of Washington. Instead, it joined forces with Texas businesses that sell the products and sued there. The conservative 5th U.S. Circuit Court of Appeals allowed the lawsuit to go forward, finding that anyone whose business is hurt by the FDA decision can sue. The agency appealed to the Supreme Court, arguing that R.J. Reynolds was attempting to find a court favorable to its arguments, a practice often referred to as 'judge shopping.' The justices, though, found that the law does allow other businesses affected by the FDA decisions, like e-cigarette sellers, to sue in their home states. In a dissent, Justice Ketanji Brown Jackson, joined by Justice Sonia Sotomayor, said she would have sided with the agency and limited where the cases can be filed. The Campaign for Tobacco-Free Kids called the majority decision disappointing, saying it would allow manufacturers to 'judge shop,' though it said the companies will still have to contend with the Supreme Court's April decision. Attorney Ryan Watson, who represented R.J. Reynolds, said that the court recognized that agency decisions can have devastating downstream effects on retailers and other businesses, and the decision 'ensures that the courthouse doors are not closed' to them. ___
Yahoo
an hour ago
- Yahoo
Children's cough medicine recalled, may cause food poisoning: FDA
(WJW) – A nationwide recall of a popular children's cough medicine has been announced due to a microbial contamination, which the U.S. Food and Drug Administration warns could cause two types of foodborne illnesses. According to the recall alert, Medtech Products Inc., a Prestige Consumer Healthcare Inc. company, is voluntarily recalling five lots of Little Remedies Honey Cough Syrup due to the presence of Bacillus cereus and loss of shelf-stability. Ready-to-eat meals sold at Walmart and Kroger recalled after multiple deaths The Cleveland Clinic describes Bacillus cereus as a microscopic organism that can cause food poisoning. 'One type is characterized by nausea, vomiting, and stomach cramps that can start 1 to 6 hours after eating or drinking contaminated food. The second type can cause stomach cramps and diarrhea that can start 8 to 16 hours after eating or drinking contaminated food,' states the recall alert. 'Diarrhea may be a small volume or profuse and watery. Although healthy individuals may suffer only short-term illness, exposure to high levels of foodborne B. cereus can cause death.' Browns rookie QB cited for speeding over 100 mph According to the FDA, the affected lots were distributed nationwide through retailers and online from Dec. 14, 2022, through June 4, 2025. Here's what to look for: Item UPC Lot # Exp. Date 7-56184-10737-9 0039 11/2025 0545 01/2026 0640 02/2026 0450 05/2026 1198 12/2026 'All lots of Little Remedies® Honey Cough 4 FL OZ (118 mL) still within expiry are being included in the scope of the recall,' reports the FDA. 'This recall does not include any other Little Remedies® products.' Consumers who have the recalled product are advised to stop using it 'immediately' and should contact their physician or healthcare provider if they experience any problems that may be related to the product. The FDA states that the company will offer reimbursement for consumers who have purchased products from the recalled lots. CLICK HERE to learn more. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Newsweek
3 hours ago
- Newsweek
How Animal Testing in US Could Be Transformed Under Trump
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Millions of animals each year are killed in U.S. laboratories as part of medical training and chemical, food, drug and cosmetic testing, according to the non-profit animal rights organization People for the Ethical Treatment of Animals (PETA). For many animals held captive for research, including a huge range of species from dogs, cats and hamsters to elephants, dolphins and many other species, pain is "not minimized," U.S. Department of Agriculture data shows. The issue of animal testing is something most Americans agree on: it needs to change and gradually be stopped. A Morning Consult poll conducted at the end of last year found that 80 percent of the 2,205 participants either agreed or strongly agreed with the statement: "The US government should commit to a plan to phase out experiments on animals." Since President Donald Trump began his second term, his administration has been making moves to transform and reduce animal testing in country, although the question remains as to whether it will be enough to spare many more animals from pain and suffering this year. Animal Testing In US Could Be Transformed Animal Testing In US Could Be Transformed Photo-illustration by Newsweek/Getty/Canva What Is The Trump Administration Doing About It? There have been various steps taken in different federal agencies to tackle the issue of animal testing since Trump was sworn in on January 20. In April, the Food and Drug Administration (FDA) announced it was "taking a groundbreaking step to advance public health by replacing animal testing in the development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods." The FDA said that its animal testing requirement will be "reduced, refined, or potentially replaced" with a range of approaches, including artificial intelligence-based models, known as New Approach Methodologies or NAMs data. A Department of Health and Human Services (HHS) official told Newsweek: "The agency is paving the way for faster, safer, and more cost-effective treatments for American patients. "As we restore the agency's commitment to gold-standard science and integrity, this shift will help accelerate cures, lower drug prices, and reaffirm U.S. leadership in ethical, modern science." The National Institutes of Health (NIH) announced it was "adopting a new initiative to expand innovative, human-based science while reducing animal use in research," in alignment with the FDA's initiative. The agency said that while "traditional animal models continue to be vital to advancing scientific knowledge," new and emerging technologies could act as alternative methods, either alone or in combination with animal models. The NIH Office of Extramural Research told Newsweek it was "committed to transparently assessing where animal use can be reduced or eliminated by transitioning to [new approach methodologies (NAMs)]." "Areas where research using animals is currently necessary represent high-priority opportunities for investment in NAMs," the agency added. It added that it will "further its efforts to coordinate agency-wide efforts to develop, validate, and scale the use of NAMs across the agency's biomedical research portfolio and facilitate interagency coordination and regulatory translation for public health protection." During Trump's first term, the Environmental Protection Agency (EPA) signed a directive to "prioritize efforts to reduce animal testing and committed to reducing testing on mammals by 30 percent by 2025 and to eliminate it completely by 2035," an EPA spokesperson told Newsweek. Although, the spokesperson added: "the Biden Administration halted progress on these efforts by delaying compliance deadlines." As a member of the House, Lee Zeldin, the EPA's current administrator, co-sponsored various bills during Trump's first term regarding animal cruelty, covering issues such as phasing out animal-based testing for cosmetic products; ending taxpayer funding for painful experiments on dogs at the Department of Veteran Affairs; empowering federal law enforcement to prosecute animal abuse cases that cross state lines; and others, the spokesperson said. What The Experts Think Needs To Be Done The Trump administration's efforts to tackle the issue of animal testing appear to be a step in the right direction, according to experts who spoke with Newsweek. "I was pleasantly surprised and quite frankly a bit shocked to read the simultaneous announcements by the NIH and the FDA regarding a new emphasis on the use of alternatives to animals," Jeffrey Morgan, a professor of pathology and laboratory medicine at Brown University in Rhode Island, told Newsweek. Morgan, who is also the director of the Center for Alternatives to Animals in Testing at Brown University, said that both agencies are moving together in the same direction on the issue "sends a unified and very powerful message to the research and biotech communities." He added that the announcements showed "a major acknowledgement of the limitations of the use of animals in research and testing." "What is especially exciting is that the NIH announcement will encourage the entry of new investigators into the field, further accelerating innovation in alternatives with exciting impacts for both discovery and applied research across all diseases," he said. He added that the FDA announcement and its emphasis on a new regulatory science that embraces data from alternatives was "equally exciting." "The demands of this new regulatory science will likewise accelerate innovation because it will establish the much-needed regulatory framework for the rigorous evaluation of data from alternatives," he said. While the administration's initiatives to shift research away from animal testing is heading in the right direction, its policies are "overdue," Dr. Thomas Hartung, a professor in the department of environmental health and engineering at Johns Hopkins Bloomberg School of Public Health, Maryland, told Newsweek. "The animal tests for safety were introduced more than 50 years ago. There is no other area of science where we do not adapt to scientific progress," he said. Hartung added that animal "testing takes too long and is too expensive to really provide the safety consumers want." He said that running animal tests for new chemicals can cost millions and take years in some cases. "Nobody can wait that long, even if they can afford the testing costs," he said. Hartung also believes the shifts in the industry to reduce animal testing have been "coming for a while," as over the last two decades, America's opposition to animal use in medical research has been increasing. "The alignment of FDA and NIH really makes the difference now, which I think is evidence of a strong relationship of their leaderships," he said. Yet in order to make a real difference, Hartung said clear deadlines are key to show that "this is not just lip service." He also said that he thought "the transformative nature of artificial intelligence in this field is not fully acknowledged." "We also need an objective framework for change to better science, such as the evidence-based toxicology approach," he said.
